Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Robert Somerville"'
Autor:
Norris Lam, Steven A. Rosenberg, John J. Rossi, James N. Kochenderfer, Adrian Bot, Robert Somerville, James Chih-Hsin Yang, Richard M. Sherry, Steven A. Feldman, Lori McIntyre, Tangying Lu
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 25(10)
T cells expressing anti-CD19 chimeric antigen receptors (CARs) can induce complete remissions (CRs) of diffuse large B cell lymphoma (DLBCL). The long-term durability of these remissions is unknown. We administered anti-CD19 CAR T cells preceded by c
Autor:
Lori McIntyre, Jonathan W. Friedberg, Mark Roschewski, Udai S. Kammula, Stephanie L. Goff, Christopher A. Klebanoff, Richard M. Sherry, Robert Somerville, James N. Kochenderfer, Adrian Bot, Steven A. Feldman, Marika Sherman, Tatyana Feldman, Victoria Shi, Steven A. Rosenberg, Tangying Lu, Arianne Perez, John J. Rossi, Mary Ann Toomey, James Chih-Hsin Yang, Constance M. Yuan, Allen Xue
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(16)
Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 T cells have been publ
Autor:
Steven A. Rosenberg, Tangying Lily Lu, Omar Pugach, Robert Somerville, Steven A. Feldman, James N. Kochenderfer, Marc Better
Publikováno v:
Human gene therapy methods. 27(6)
The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1–6) The anti-CD19 CAR-T cell pro
Autor:
Steven A. Rosenberg, Victoria Shi, Tangying L. Lu, Roger Kurlander, R. E. Gress, Brenna G. Hansen, Dennis D. Hickstein, Jeremy J. Rose, Steven A. Feldman, Jennifer N. Brudno, David Halverson, Bazetta Blacklock-Schuver, Irina Maric, Jennifer S. Wilder, Daniel H. Fowler, Robert Somerville, Juan C. Gea-Banacloche, Frances T. Hakim, Steven Z. Pavletic, James N. Kochenderfer, Andre Goy, Alexander T. Iwamoto
Purpose Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78731f1c73af0683f0b5eca4e5d2e804
https://europepmc.org/articles/PMC4872017/
https://europepmc.org/articles/PMC4872017/